# Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims.

#### What Is Claimed Is:

1-10. (Canceled).

- 11. (Currently amended) An isolated polypeptide comprising a first amino acid sequence at least 95% identical to a second amino acid sequence selected from the group consisting of:
- (a) a full length polypeptide of SEQ ID NO: 408 or a full length polypeptide encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No. 203071\_corresponding to SEQ ID NO: 408;
- (b) a secreted form of SEQ ID NO: 408 or a secreted form of the polypeptide encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No. 203071\_corresponding to SEQ ID NO: 408;
- (c) a polypeptide fragment of at least 30 <u>contiguous</u> amino acids of SEQ ID NO: 408 or a polypeptide fragment of at least 30 <u>contiguous</u> amino acids encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No. 203071 corresponding to SEQ ID NO: 408, wherein said fragment <u>promotes angiogenesishas biological activity</u>;
- (d) a polypeptide fragment of at least 50100 contiguous amino acids of SEQ ID NO: 408\_or a polypeptide fragment of at least 50100 contiguous amino acids encoded by the HACCI17\_cDNA Clone ID in ATCC Deposit No. 203071 corresponding to SEQ ID NO: 408, wherein said fragment promotes angiogenesishas biological activity;
  - (e) a polypeptide comprising amino acids 1-218 of SEQ ID NO: 408;
  - (f) a polypeptide comprising amino acids 25-218 of SEQ ID NO: 408; and
- (g) a polypeptide comprising the mature form of HACCI17 polypeptide encoded by the HACCI17 cDNA in ATCC Deposit No. 203071.
- 12. (Previously presented) The polypeptide of claim 11, wherein said polypeptide comprises a heterologous amino acid sequence.

13-15. (Canceled).

16. (Previously presented) An isolated polypeptide produced by a method comprising:

Docket No.: PS901

- (a) expressing the polypeptide of claim 11 by a cell; and
- (b) recovering said polypeptide.

### 17-20. (Canceled)

- 21. (Withdrawn) A method for identifying a binding partner to the polypeptide of claim 11 comprising:
  - (a) contacting the polypeptide of claim 11 with a binding partner; and
- (b) determining whether the binding partner effects an activity of the polypeptide.

## 22-23. (Canceled)

- 24. (Previously presented) The product produced by the method of claim 21.
- 25. (Currently amended) An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a full length polypeptide of SEQ ID NO: 408 or a full length polypeptide encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No. 203071 corresponding to SEQ ID NO: 408;
- (b) a secreted form of SEQ ID NO: 408 or a secreted form of the polypeptide encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No. 203071 corresponding to SEQ ID NO: 408;
- (c) a polypeptide fragment of at least 30 <u>contiguous</u> amino acids of SEQ ID NO: 408 or a polypeptide fragment of at least 30 <u>contiguous</u> amino acids encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No. 203071 corresponding to SEQ ID NO: 408, wherein said fragment <u>promotes angiogenesishas biological activity</u>;
- (d) a polypeptide fragment of at least 50100 contiguous amino acids of SEQ ID NO: 408 or a polypeptide fragment of at least 50100 contiguous amino acids encoded by the HACCI17 cDNA Clone ID in ATCC Deposit No. 203071 corresponding to SEQ ID NO: 408, wherein said fragment promotes angiogenesishas biological activity;
  - (e) a polypeptide comprising amino acids 1-218 of SEQ ID NO: 408;
  - (f) a polypeptide comprising amino acids 25-218 of SEQ ID NO: 408; and

Docket No.: PS901

- (g) a polypeptide comprising the mature form of HACCI17 polypeptide encoded by the HACCI17 cDNA in ATTC Deposit No. 203071.
- 26. (Previously presented) The polypeptide of claim 25, wherein said polypeptide comprises a heterologous amino acid sequence.
- 27. (Previously presented) The polypeptide of claim 11, wherein said polypeptide is glycosylated.
- 28. (Previously presented) The polypeptide of claim 25, wherein said polypeptide is glycosylated.
- 29. (Previously presented) An isolated polypeptide produced by the method comprising:
  - (a) expressing the polypeptide of claim 25 by a cell; and
  - (b) recovering said polypeptide.

# 30. (Canceled)

- 31. (Withdrawn) A method for identifying a binding partner to the polypeptide of claim 25 comprising:
  - (a) contacting the polypeptide of claim 25 with a binding partner; and
  - (b) determining whether the binding partner effects an activity of the polypeptide.
  - 32. (Withdrawn) The product produced by the method of claim 31.